FDA and EMA Discussed Botanical Drug Pathways
Regulators met to address the divergence between U.S. and European approval standards for botanical therapies.
Updated on Sept. 25, 2026 in Botany
Live Poll
Should government agencies simplify approval processes to make new herbal or botanical drugs more accessible?
The FDA and the European Medicines Agency held a meeting in Amsterdam to explore ways to streamline the regulatory pathways for botanical drugs. This development remains at the discussion stage as global regulators analyze differing manufacturing requirements.
Why it matters
The meeting aimed to address the high barriers to entry for plant-based medicines, which currently face significantly different quality control standards in the U.S. and the EU. Reconciling these approaches could clarify how researchers bring complex, multi-component therapies to market.
The FDA mandates rigorous characterization of substances to ensure minimal batch-to-batch manufacturing variation, while the EMA relies on safety data from traditional products already on the market. Approval costs for the former are reported to be 10 times higher than the latter.
The players
FDA
The U.S. agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
European Medicines Agency
The EU body responsible for the scientific evaluation, supervision, and safety monitoring of medicines developed for use within the European Union.
The details
The FDA regulates botanical drugs under the Food, Drug and Cosmetic Act, which requires detailed proof of manufacturing consistency. By contrast, the EMA utilizes a safety information approach based on products that have established histories of use. For the drug FILSUVEZ, which contains birch triterpenes—natural compounds found in the outer bark of birch trees—the FDA demanded strict batch-to-batch variation limits, while the EU required standardization to a single terpene.
Timeline
September 25, 2026: The FDA and EMA held a meeting regarding botanical drug market pathways.
The Tech Race
The meeting follows a long-standing divergence between U.S. and EU regulatory frameworks governed by the Food, Drug and Cosmetic Act. Industry participants are watching whether these jurisdictions can move toward a unified standard that eases the burden of manufacturing validation.
The meeting does not immediately change market availability or drug pricing for patients. It establishes the groundwork for potential future policy shifts that could influence the speed at which novel botanical treatments enter the medical ecosystem.
The takeaway
Regulators are actively evaluating whether the current, high-cost approval process can be simplified for complex botanical therapies. Observers should monitor the official meeting recording, which organizers stated will be made available to the public.
Further reading
For broader context on current standards and classification, visit our page on Botany.
Live Poll
Should government agencies simplify approval processes to make new herbal or botanical drugs more accessible?
